An observational study in Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis and Allergic Asthma, sponsored by Allergy Therapeutics. Active, not recruiting at 1 site in Germany. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Allergy Therapeutics · Observational
The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial posology.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
This study's enrollment of 320 is above the median of 86 across 32 observational studies indexed under Rhinitis, Allergic, Seasonal.
Browse Rhinitis, Allergic, Seasonal studies →Allergy Therapeutics is the lead sponsor of 27 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adults, adolescents and children from the age of 5 on, who are going to be treated with TA Bäume or TA Gräser.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
adult patients aged ≥ 18 with rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, caused by an IgE-mediated allergy to grass/rye or tree pollen; who are treated with MATA grass or MATA trees as part of their routine medical care
Drug: MATA trees or MATA grass
children aged from \>5 to 17 years with rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, caused by an IgE-mediated allergy to grass/rye or tree pollen; who are treated with MATA grass or MATA trees as part of their routine medical care
Drug: MATA trees or MATA grass
Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids
Also known as: TA Gräser, TA Bäume
change in the combined symptom medication score (CSMS)
The primary endpoint is the change in the total combined symptom medication score (CSMS) during the entire study period, determined from the rhinoconjunctivitis daily symptom score (dSS) and rhinoconjunctivitis daily medication score (dMS), averaged over the respective peak pollen season
Time frame: once a year for 5 years
rhinoconjunctivitis daily medication score
the changes in use of daily anti-allergic medication needed, averaged over the respective peak pollen season
Time frame: once a year for 5 years
rhinoconjunctivitis daily symptom score
allergic symptoms and severity will be self-recorded by the subject in an eDiary on a daily basis during the pollen season, averaged over the respective peak pollen season
Time frame: once a year for 5 years
Rhinoconjunctivitis Quality of Life
The change in quality of life as assessed by the standardised Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(s))
Time frame: twice a year for 5 years
Rhinitis Control
change in symptom control of rhinitis assessed by Rhinitis Control Assessment Test (RCAT)
Time frame: twice a year for 5 years
Asthma Control
The change of asthma control in asthmatic patients assessed by the (Childhood) Asthma Control Test (C-ACT/ACT)
Time frame: twice a year for 5 years
Incidence of Treatment-Emergent Adverse Events (safety and tolerability)
frequency and severity of Treatment-Emergent adverse events
Time frame: all year for 3 years
treatment satisfaction
directly assessed by the physician (questionnaire)
Time frame: once after 3 years and once after 5 years
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rhinitis, Allergic, Seasonal →